BRAF and neoplasm: We report here the development, validation, and clinical implementation of a multiplexed assay designed to simultaneously detect 43 recurrent mutations in BRAF, KIT, NRAS, GNA11, GNAQ, and CTNNB1 using tumor-derived DNA from formalin-fixed paraffin-embedded (FFPE) tissues.